Replimune Announces Pricing of Upsized Public Offering

REPL 11.26.2024

Full Press ReleaseSEC FilingsOur REPL Tweets

About Gravity Analytica

Recent News

  • 01.21.2025 - Replimune Announces Biologics License Application Acceptance and Priority Review for RP1 for the Treatment of Advanced Melanoma
  • 01.13.2025 - 43rd Annual J.P. Morgan Healthcare Conference
  • 01.10.2025 - Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Recent Filings

  • 01.17.2025 - S-8 Securities to be offered to employees in employee benefit plans
  • 12.18.2024 - 4 Statement of changes in beneficial ownership of securities
PDF Version

BOSTON,Nov. 25, 2024(GLOBE NEWSWIRE) --Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the pricing of its public offering of 6,923,000 shares of its common stock at a public offering price of$13.00per share. In addition, in lieu of common stock to certain investors,Replimunetoday announced the pricing of its public offering of pre-funded warrants to purchase 3,846,184 shares of its common stock at a purchase price of$12.9999per pre-funded warrant, which equals the public offering price per share of the common stock less the$0.0001per share exercise price of each pre-funded warrant. The aggregate gross proceeds from the offering are expected to be approximately$140 million, before deducting the underwriting discounts and commissions and offering expenses payable byReplimune. All securities in the offering are being offered byReplimune. In addition,Replimunehas granted the underwriter a 30-day option to purchase up to an additional 1,615,377 shares of its common stock fromReplimuneat the public offering price, less the underwriting discounts and commissions. The offering is expected to close onNovember 27, 2024, subject to the satisfaction of customary closing conditions.

Leerink Partnersis acting as sole bookrunning manager for the offering.

A preliminary prospectus supplement relating to and describing the terms of the offering was filed with theSecurities and Exchange Commission(the “SEC”) onNovember 25, 2024. The final prospectus supplement relating to the offering will be filed with theSEC. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained, when available, by visiting EDGAR on theSECwebsite atwww.sec.gov. Alternatively, copies of the preliminary prospectus supplement and the accompanying prospectus, when available, may be obtained fromLeerink Partners LLC, Attention:Syndicate Department,53 State Street, 40th Floor,Boston, Massachusetts02109, by telephone at + 1 (800) 808-7525, ext. 6105, or by email atsyndicate@leerink.com. The final terms of the offering will be disclosed in a final prospectus supplement to be filed with theSEC.

The securities described above are being offered by Replimune pursuant to its shelf registration statement on Form S-3, including a base prospectus, that was previously filed by Replimune with the SEC on August 3, 2023, as amended by the Post-Effective Amendment No. 1 filed with theSEConMay 16, 2024, and as further amended by the Post-Effective Amendment No. 2 filed with theSEConMay 16, 2024, and declared effective by the SEC on July 22, 2024. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of securities, in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

AboutReplimune

Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment to ignite a strong and durable systemic response. The RPx product candidates are expected to be synergistic with most established and experimental cancer treatment modalities, leading to the versatility to be developed alone or combined with a variety of other treatment options.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the timing of closing of our public offering, the gross proceeds we expect to receive from our public offering and other statements identified by words such as “could,” “expects,” “intends,” “may,” “plans,” “potential,” “should,” “will,” “would,” or similar expressions and the negatives of those terms. Forward-looking statements are not promises or guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in such forward-looking statements. These factors include risks related to our limited operating history, our ability to generate positive clinical trial results for our product candidates, the costs and timing of operating our in-house manufacturing facility, the timing and scope of regulatory approvals, the availability of combination therapies needed to conduct our clinical trials, changes in laws and regulations to which we are subject, competitive pressures, our ability to identify additional product candidates, political and global macro factors including the impact of the coronavirus as a global pandemic and related public health issues and the Russian-Ukrainian and Israel-Hamas political and military conflicts, and other risks as may be detailed from time to time in our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q and other reports we file with the SEC, and in the preliminary prospectus supplement and the accompanying prospectus, once filed with theSEC. Our actual results could differ materially from the results described in or implied by such forward-looking statements. Forward-looking statements speak only as of the date hereof, and, except as required by law, we undertake no obligation to update or revise these forward-looking statements.

Investor InquiriesChris BrinzeyICR Westwicke339.970.2843chris.brinzey@westwicke.com

Media InquiriesArleen GoldenbergReplimune917.548.1582media@replimune.com

Replimune Group Inc

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com